Why C-Peptide Should Be Measured in DKA
C-peptide measurement in DKA is essential for determining the degree of residual β-cell function, which directly impacts diabetes classification, prognosis, and long-term management decisions—particularly distinguishing type 1 from type 2 diabetes and predicting future insulin requirements.
Primary Diagnostic Purpose
C-peptide serves as a marker of endogenous insulin secretion because it is co-secreted with insulin in equimolar amounts but is not affected by exogenous insulin administration 1, 2. In the context of DKA, measuring C-peptide helps:
Diabetes Type Classification
- Low or undetectable C-peptide (<200 pmol/L or <0.6 ng/mL) indicates severe β-cell destruction consistent with type 1 diabetes 2
- Higher C-peptide levels (>600 pmol/L or >1.8 ng/mL) suggest type 2 diabetes or ketosis-prone type 2 diabetes, even when presenting with DKA 2, 3
- Intermediate values (200-600 pmol/L) are indeterminate and may represent type 1 diabetes, MODY, or insulin-treated type 2 diabetes 2
Prognostic Value
Children with DKA at diagnosis who have lower C-peptide levels demonstrate significantly worse residual β-cell function, higher insulin requirements, lower remission rates, and higher HbA1c during follow-up 4, 5. This relationship is particularly pronounced in children under 2 years of age, where 71% present with DKA and have the lowest C-peptide levels compared to older children 4.
Clinical Implications for Management
Predicting Insulin Dependency
- C-peptide <20 μg/day (or <0.6 ng/mL in serum) after recovery from DKA is an index of insulin dependency 6
- Patients with normal C-peptide levels (>59 μg/day) after DKA recovery may ultimately be controlled with diet or oral agents, suggesting they have type 2 rather than type 1 diabetes 6
Long-term Outcomes
Even minimal residual C-peptide secretion (≥30 pmol/L) provides clinical benefits in type 1 diabetes 7:
- 27% lower insulin dose requirements when C-peptide ≥200 vs <5 pmol/L 7
- 4.9 mmol/mol lower HbA1c during follow-up 7
- 56% reduction in odds of serious hypoglycemic episodes (OR 0.56) 7
- 44% reduction in hazard for hospital admission for DKA (HR 0.44) 7
- 49% reduction in odds of incident retinopathy (OR 0.51) 7
Important Caveats
Timing of Measurement
Do not test C-peptide within 2 weeks of a hyperglycemic emergency 2, 3. During acute DKA, β-cell function may be temporarily suppressed, leading to falsely low C-peptide levels even in patients with type 2 diabetes 8, 6. One study showed C-peptide as low as 6 μg/day during ketoacidosis in a patient who ultimately had type 2 diabetes, with restoration of normal C-peptide after recovery 6.
Testing Conditions
- A random C-peptide sample (with concurrent glucose) within 5 hours of eating can replace formal stimulation testing 2, 3
- If result is <600 pmol/L and concurrent glucose is <4 mmol/L (<70 mg/dL) or the person may have been fasting, consider repeating the test 2, 3
- Very low levels (<80 pmol/L or <0.24 ng/mL) do not need to be repeated 2, 3
Differential Patterns in DKA vs HHS
Recent evidence shows that hyperglucagonemia patterns differ based on C-peptide levels 9:
- In DKA with type 1 diabetes, plasma glucagon levels negatively correlate with C-peptide/glucose ratio (ρ = -0.67), suggesting that insulin deficiency drives glucagon excess 9
- In HHS, plasma glucagon levels positively correlate with C-peptide/glucose ratio (ρ = 0.71), indicating a different pathophysiologic mechanism 9
- Mean C-peptide was 0.9 ng/dL in DKA versus 2.7 ng/dL in HHS 8
Practical Algorithm
When a patient presents with DKA:
- Stabilize and treat the acute metabolic emergency first 2
- Wait at least 2 weeks after DKA resolution before measuring C-peptide 2, 3
- Obtain random C-peptide with concurrent glucose (preferably within 5 hours of eating) 2, 3
- Interpret results in context of age, BMI, and clinical features:
- Consider islet autoantibodies (GAD, IA-2, ZnT8) if diagnosis remains unclear 2, 10